| Project/Area Number |
23591168
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Shigeki 川崎医科大学, 医学部, 講師 (10295206)
MOURI Keiji 川崎医科大学, 医学部, 講師 (20341092)
ABE Masaaki 川崎医科大学, 医学部, 臨床助教 (50509221)
IKEDA Masaki 川崎医科大学, 医学部, 臨床助教 (90551135)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 結核感染診断法 / クオンティフェロン / T-SPOT.TB / サイトカイン / ケモカイン / 局所検体 / ＱｕａｎｔｉＦＥＲＯＮ / IGRA |
|---|
| Outline of Final Research Achievements |
The challenge of development of useful new diagnostic methods for tuberculosis infection.
1)In order to increse the sensitivity and specificity, we measured the colony forming unit of IFN-γ produced by the stimulation of Mycobacterium tuberculosis (MTB)-specific antigen after the isolation of monocytes using the clinical specimens from the inflammation sites. As a result, when we used pleural effusion, highest sensitivity was obtained comparing to other diagnostic methods.
2)We measured several cytokines and chemokinesin the supernatant stimulated by MTB-specific antigens. IP-10 and MIG were useful to differentiate active TB disease and other diseases as well as IFN-γ. On the other hand, IL-2 showed most poor results. If the new diagnostic kit which can be measured IP-10 and IL-2 with IFN-γ simultaneously was developed, it may be possible to discriminate active TB disease and latent TB disease or healed TB disease in future.
|
